Eugene Washington appointed to J&J Board of directors
November 13, 2012Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Eugene Washington, J&J, JJ
Dr Eugene Washington has been appointed to the Board of directors at Johnson & Johnson. Washington serves as vice chancellor …
AstraZeneca signs genome deal
November 13, 2012Research and Development, Sales and Marketing AstraZeneca, Foundation, SMIP
AstraZeneca has signed a genomic profiling agreement with US molecular information company Foundation Medicine. The collaboration will use its FoundationOne …
EFCG calls for mandatory inspection of API plants
November 13, 2012Manufacturing and Production API, EFCG, EU, FMD
The European Fine Chemicals Group (EFCG) has called for all active pharmaceutical ingredient (API) manufacturing facilities to undergo mandatory inspections. …
Hospira on track to return propofol to market
November 13, 2012Manufacturing and Production Ball, Hospira, Teva
Shortages of the short-acting anaesthetic propofol in the US could be helped by the return to market of a generic …
NHS Commissioning Board appoints Patients and Information directors
November 13, 2012Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Coulthard, NHS, NHS Commissioning Board
The NHS Commissioning Board has made a series of appointments to complete its director-level recruitment to the Patients & Information …
Pharma can help NHS transition, says partnership leader
November 13, 2012Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing ABPI, CCGs, Conference, NHS, PCT
A new ABPI team is now ready to help the pharmaceutical industry forge partnerships with the NHS, even as the …
Patients ‘shut out’ of drug price talks
November 13, 2012Sales and Marketing Cancer, NHS, NICE, VBP, prostate
Patients are being excluded from the negotiations between government and the pharma industry on the introduction of Value-Based Pricing (VBP).That …
Pfizer and GSK end agreements
November 12, 2012Research and Development, Sales and Marketing Auxilium, GSK, Pfizer, Xenoport
Pfizer and GlaxoSmithKline are both handing back the rights to two drugs in April 2013 as part of the termination …
Havas Health launches new Global Agency Group, Havas Lynx
November 12, 2012Medical Communications
Euro RSCG Life 4D and Creative Lynx join to form new Global Brand for the next era in Health and …
Contract research news in brief
November 12, 2012Research and Development Bay Bioanalytical Laboratory, Bioclinica, Charles River, ICON, Pacific BioLabs, Quintiles, Vital River
Acquisitions for Charles River and Pacific BioLabs, a new contract for Bioclinica plus updates from Icon and Quintiles.
immatics appoints Peter Chambré as chairman
November 12, 2012Manufacturing and Production, Research and Development, Sales and Marketing Peter Chambre, immatics
Biotech development firm immatics has announced the appointment of Peter Chambré as chairman of the Board. Chambré has had extensive …
NHS: pharma needs to help more
November 12, 2012Sales and Marketing CCGs, NHS, pharma
A variety of senior figures in public health set out how they want the pharma industry to do more to …
Copper could replace precious metals in pharma production
November 9, 2012Manufacturing and Production Sweden, copper, manufacturing
Non-precious metals such as copper could be used as catalysts in pharmaceuticals production, replacing precious metals that are expensive and …
GSK guilty of off-label promotion
November 9, 2012Medical Communications, Sales and Marketing GSK, PMCPA, Revolade
GlaxoSmithKline has been found to have breached three clauses in the ABPI Code of Practice following a complaint from a …
Pharma treated as though ‘selling cyanide’
November 9, 2012Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing ABPI, NHS, Stephen Whitehead
APBI chief executive Stephen Whitehead claimed that pharma companies are sometimes made to feel as though they are manufacturing poison …
Astellas appoints VP of Scientific and Medical Affairs
November 9, 2012Manufacturing and Production, Research and Development, Sales and Marketing Astellas, Jeffrey Bloss
Astellas has announced Jeffrey Bloss has joined the company as vice president of its Scientific and Medical Affairs (ASMA) division. …
Leadership changes at Teva
November 8, 2012Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Levin, Teva
Teva Pharmaceutical has announced some management changes to its executive leadership team. Allan Oberman, senior vice president of North America …
Janssen and GSK in hep C tie-ups
November 8, 2012Research and Development, Sales and Marketing GSK, Janssen, Vertex, hep C
Janssen and GlaxoSmithKline are to conduct separate Phase II studies with Vertex Pharmaceuticals to test an investigational all-oral regimen to …
Goldacre is right – greater honesty is needed
November 7, 2012Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Bad pharma, Goldacre, Les Rose
One of the most trenchant critics of pseudo-science in healthcare, the neuro-psychologist Dr Ben Goldacre, has turned his guns on …
‘Patchy’ NHS Constitution needs improving
November 7, 2012Sales and Marketing DoH, Future Forum, NHS, commissioning
The NHS Future Forum has criticised the NHS Constitution for not being up to scratch and suggested ‘essential steps’ to …
Latest content
Global coalition calls for stronger government action on COPD
Global health researchers call for more equitable partnerships
Liverpool launches £20m lab for infectious disease drug discovery
Circle Health Group expands into UK laboratory operations
FibroFind appoints Professor Andrew Fisher as Chief Medical Officer
